An environmental scan (ES) is an efficient mixed-methods approach to collect and interpret relevant data for strategic planning and project design. To date, the ES has not been used nor evaluated in the clinical cancer genetics setting. We created and implemented an ES to inform the design of a quality improvement (QI) project to increase the rates of adherence to national guidelines for cancer genetic counseling and genetic testing at three unique oncology care settings (OCS). The ES collected qualitative and quantitative data from reviews of internal processes, past QI efforts, the literature, and each OCS. The ES used a data collection form and semistructured interviews to aid in data collection. The ES was completed within 6 months, and sufficient data were captured to identify opportunities and threats to the QI project's success, as well as potential barriers to, and facilitators of guideline-based cancer genetics services at each OCS. Previously unreported barriers were identified, including inefficient genetic counseling appointment scheduling processes and the inability to track referrals, genetics appointments, and genetic test results within electronic medical record systems. The ES was a valuable process for QI project planning at three OCS and may be used to evaluate genetics services in other settings.
Introduction
The National Academy of Sciences has recommended that all health care providers pursue quality improvement (QI) efforts to increase the safety, effectiveness, patient-centeredness, timeliness, efficiency, and equity of care (Institute of Medicine 2001) . Health care providers in the USA have used QI to increase patient safety, make clinical processes more efficient, and improve adherence to practice guidelines (Girdler et al. 2016 ). Specific to oncology care, the Commission on Cancer recommends that to obtain accreditation, a health care organization must perform studies of quality and quality improvement projects, per Standard 4.8 (Commission on Cancer 2016).
Guidelines for determining who may benefit from genetic counseling and germline genetic testing for hereditary cancer predisposition syndromes have been available for several years from the National Comprehensive Cancer Network (NCCN) and numerous professional organizations (Hampel et al. 2015; Lancaster et al. 2015; Lu et al. 2014; National Comprehensive Cancer Network 2017a , 2017b Robson et al. 2010; Society of Gynecologic Oncology 2014a , 2014b . However, adherence to these guidelines is poor, even among patients diagnosed with cancer who may benefit directly from genetic testing. Among the primary cancer types associated with the Centers for Disease Control and Prevention Tier 1 conditions (Hereditary Breast and Ovarian Cancer syndrome and Lynch syndrome), studies have estimated that only 12-50% of patients with epithelial ovarian cancer and 34-60% of patients with breast cancer who meet the NCCN guidelines for genetic testing ultimately undergo that testing, with similar rates of recommended tumor screening (microsatellite instability and immunohistochemistry testing for mismatch repair proteins) for Lynch syndrome among patients with colorectal and endometrial cancers (Batte et al. 2014; Beamer et al. 2012; Chun et al. 2016; Cragun et al. 2015; Febbraro et al. 2015; Irons et al. 2017; Karlitz et al. 2015; Kurian et al. 2017; McCarthy et al. 2016; Modell et al. 2016; Petzel et al. 2014; Powell et al. 2013; Stuckey et al. 2014; Wright et al. 2016) . A significant gap exists between the guidelines for who should receive genetics services, and the proportion of eligible patients who actually receive a recommendation for, and access to, guideline-based cancer genetics services. Quality improvement is one approach that can be used to close this gap and improve the equity of cancer genetics care for patients with cancer.
MD Anderson Cancer Center initially found low rates of adherence to guideline-based provision of genetics services for patients with high-grade, non-mucinous epithelial ovarian, fallopian tube, and primary peritoneal cancer (HGOC) prompting the completion of a 3-year universal genetic testing initiative that successfully increased rates of referral, genetic counseling, and BRCA1 and BRCA2 genetic testing to greater than 85% in this patient population (Bednar et al. 2017; Meyer et al. 2010) . Concurrently, other research efforts at MD Anderson focused on delivering genetics services to patients with triple-negative breast cancer (TNBC), with results demonstrating similarly increased rates of guideline adherence. The efforts focused specifically on HGOC and TNBC due to the higher rates of germline BRCA1 and BRCA2 mutations in these cancer subtypes (estimated 15-20% of patients with HGOC or TNBC will have a mutation), straightforward NCCN guidelines for genetic testing (diagnosis alone is sufficient to meet testing criteria), relevance of BRCA mutations to cancer treatment and clinical trials (such as poly-ADP ribose polymerase (PARP) inhibitor-based therapy), and the presence of evidence-based cancer risk management strategies if a mutation is identified (Alsop et al. 2012; Hartman et al. 2012; Pal et al. 2005) .
Given the low rates of genetic counseling and genetic testing guideline adherence in the published literature, and the success of the MD Anderson initiatives, focus shifted to the dissemination of the universal genetic testing initiative as a QI project to unique external oncology care settings. The QI project aims to assess the current rates of NCCN guideline adherence for patients with epithelial ovarian cancer and TNBC at these external oncology care settings, test the generalizability of the universal genetic testing approach, and ultimately ensure guideline-based care for patients beyond the immediate reach of MD Anderson.
A robust knowledge of the environment at each external oncology care setting was needed to appropriately plan, tailor, and support QI project dissemination. An environmental scan (ES) was created and used to gather this knowledge. An ES is a mixed-methods tool used in business, government, and public health to collect information, identify risks and opportunities, tailor strategic plans, or design programs in a flexible, rapid, comprehensive, low-cost manner (Graham et al. 2008; Rowel et al. 2005 ; Society for Human Resource Management 2012). A variety of ES techniques have been reported in the literature, and most include data collection from internal and external assessments, literature reviews, internet searches, database reviews, surveys, focus groups, and interviews (Graham et al. 2008; Rowel et al. 2005 ). An ES has yet to be used to perform needs assessments or to inform project development in the fields of clinical genetics or genetic counseling. The ES was selected to gather information for this project because of its flexibility, adaptability, and capacity to collect the comprehensive environmental knowledge required to guide QI project dissemination at each oncology care setting. The purpose of the ES was to effectively capture information and knowledge to assess an external site's clinical environment and capacity to undertake a QI project, identify barriers and facilitators to assist in brainstorming and development of future QI interventions, and to identify risks and opportunities to achieve a future QI project's goals. We describe herein the creation, implementation, and findings of an ES, specific to cancer genetics services, at three unique, external oncology care settings. In contrast to MD Anderson's status as a large, tertiary care center, we sought to collaborate with community-based health systems of varying sizes.
Methods
A project team at MD Anderson was created in February 2016 to plan, oversee, and execute the QI project dissemination. The MD Anderson team was supported by a large institutional research initiative and was composed of two cancer genetic counselors, a research data coordinator with universal genetic testing initiative experience, a public health physician consultant, a public health project consultant, and an oncologist as principal investigator. The genetic counselors acted as team leaders with oversight and support from the public health consultants and principal investigator.
Since the QI project had never been disseminated beyond MD Anderson, the project dissemination was designed as a pilot program, limited to three to four health systems, in order to test novel dissemination processes such as the cancer genetics focused ES, evaluate opportunities and threats to QI dissemination, and to determine if dissemination is feasible before expanding to additional care environments. The context and process for planning the QI project dissemination are shown in Fig. 1 .
The MD Anderson team used an existing institutional network of community hospitals and health care providers who deliver oncology care to identify collaborating sites for the QI project dissemination, called the MD Anderson Cancer Network®. The MD Anderson Cancer Network® is a program of MD Anderson Cancer Center which provides quality assurance and best practices for oncology, using evidencebased guidelines developed by MD Anderson and other quality metrics endorsed by national professional organizations such as National Quality Forum, American Society of Clinical Oncology, and Oncology Nursing Society. While MD Anderson is a large, tertiary care center focusing specifically on cancer diagnosis, treatment, and research for patients from around the world, the MD Anderson Cancer Network® hospitals and health systems primarily provide cancer diagnosis and treatment as a component of their health care system, and serve patients from their city and region. These health care environments are expected to differ in many ways from MD Anderson as well as from each other. The MD Anderson team perceived the variety of oncology care settings as an opportunity to support the vision of the MD Anderson Cancer Network® to improve best practices in cancer genetics using QI methods and to evaluate the potential for dissemination of the QI project to health care systems that may be more representative of typical oncology care in the USA.
A site was considered eligible for initial engagement when there was demonstrated interest in engaging with MD Anderson, a desire to increase research and QI capacity, and an active cancer genetic counseling service. For initial engagement, stakeholders at each site were identified and contacted between May and July of 2016 to review the QI project opportunity and the project goals and purpose. Stakeholders included physicians, genetic counselors, genetic counseling administrative and management staff, and research staff. After stakeholders agreed to participate in the QI project, the ES was completed. Following initial engagement, completion of the ES, and assessment of ES findings, a site was considered eligible for formal collaboration if there was continued interest in proceeding with the QI project, support and buy-in for the project at the site, and if the site had the initial capacity and resources to implement the QI project. The three sites described herein are now formal collaborators on the QI project. Sites did not receive financial support for the completion of the ES but did receive the ES summary documents created as part of their site assessment. Genetic counselors at each collaborating site assumed leadership roles over their site's future QI project, which included creating project teams and assisting with communication, planning, and management of the project at their location with support from physician collaborators.
The ES was the planning component of the QI dissemination pilot project. The resulting QI pilot projects for each site have been approved by the University of Texas MD Anderson Cancer Center Quality Improvement Assessment Board and by each collaborating site's institutional review board to proceed as a clinical, non-research project. The QI project was designed using the Model for Improvement framework, which includes plan-do-study-act (PDSA) cycles to guide the performance of small-scale, continuous, and measurable changes to achieve specific improvement goals (Crowl et al. 2015; Graham et al. 2008; Langley et al. 2009 ). Each site's QI project is subject to ongoing review and approval as PDSAcycles are completed and clinical interventions are developed, tested, measured, assessed, and changed.
Procedures
The ES was developed and used as the planning component of the future QI pilot projects at each site. As such, QI methods and the existing literature about the use of the ES process in other settings were used to design and structure the ES. Quality improvement methods were used to analyze and interpret ES findings. The ES was not intended nor designed to be a discrete research endeavor, and as with all QI efforts, the processes should aim to have rigorous and standardized processes to increase validity, but are not designed to systematically study populations or obtain results for the purpose of Langley et al. 2009 ).
The ES was designed to have internal and external assessment components. The internal assessment was performed by the MD Anderson team and included a review of existing MD Anderson clinical cancer genetics services, internal clinic processes, work flows, system barriers and facilitators, genetic counselor experiences in non-MD Anderson clinical environments, and lessons learned from the universal genetic testing initiative. The internal assessment was completed informally over the course of several months as the MD Anderson team met to discuss and plan the QI project dissemination. The important themes from the internal assessment were identified when specific topics occurred in multiple meetings or discussions (repetition), when discussions identified specific similarities and differences between topics, such as shared or discrepant clinic processes or genetic counselor experiences, and through critical reflection of the prior universal genetic testing initiative. Meeting notes were taken by team members to assist in reflection, and future project planning discussions.
The external assessment collected information from outside of MD Anderson by way of a literature review, a data collection form, and semi-structured interviews. Internal assessment, literature review, and creation of the data collection form were completed by the MD Anderson team between March and June of 2016.
Literature Review
A non-systematic scan of the literature was conducted by the MD Anderson team. The PubMed and SCOPUS databases were searched to collect evidence for successful genetic counseling service delivery models, interventions to improve genetics service delivery, and reported rates of adherence to national guidelines for cancer genetics services. Citation tracing was used to help identify abstracts not initially identified by searching PubMed and SCOPUS for relevant terms. The literature was searched until the MD Anderson team felt that concept saturation had been reached and that the most relevant documents had been identified. Relevant abstracts were identified and screened, resulting in 108 full-text articles reviewed, and then categorized by recurring intervention types (telephone genetic counseling, telegenetics, pre-test patient education tools, use of non-genetics providers to coordinate genetic testing, etc.). A reference document was created for use by the MD Anderson team, which listed the relevant citations for articles in each category, and served as the evidence-base upon which to approach the QI projects for each site.
Data Collection Form
A template was created by the MD Anderson team and was used to collect information about the clinical environment and cancer genetics services at each collaborating site, which was called the data collection form. The internal assessment and literature review identified a set of factors that could impact the use of cancer genetics services or the successful execution of a QI project. To create the data collection form, factors were categorized by environment level: region, hospital, oncology clinic, cancer genetic counseling clinic, and technology. For each environment level, questions were developed to assess the presence or absence of the factors of interest. Questions were developed so that the responses could be provided as a yes/no answer or a short phrase or sentence. The data collection form consisted of a word document of 130 questions (Online Resource 1). Example questions from each of the environmental levels are included in Table 1 .
Each site team received a data collection form between June and July of 2016, and were asked to provide answers to each question, as possible. Timelines for the collaborating site teams to complete the data collection form were flexible, and each site's lead genetic counselors determined what would be a reasonable timeline, which was then agreed to by the MD Anderson team. Timelines were not mandated by the MD Anderson team as an acknowledgement of the various other tasks required by the genetic counselors at each site, the potential challenges to collecting answers to the questions, and the lower priority of this activity as compared to the genetic counselors' clinical responsibilities. Site teams were able to seek assistance from their hospital resources, colleagues, or other staff to help answer questions. Questions that were unclear or could not be answered by the site teams were left unanswered. Upon completion of the form, it was returned to the MD Anderson team for review, and any relevant unanswered fields were flagged for further discussion or completed through additional external data collection from the collaborating site's website, community health needs assessments, or email correspondence with site and Cancer Network staff if possible.
Semi-Structured Interviews
Informal semi-structured interviews were conducted by the MD Anderson team with each site's team after they completed the data collection form. Interviews occurred June through August of 2016. Interview topics were drawn from the data collection form, and primarily focused on questions that had unclear or incomplete answers, complex clinical processes that could not be effectively captured by the question and answer format of the form, and clinic structures which required discussion about the networks of individuals, clinics, and their processes. The interviews were conducted via teleconferencing and were not recorded nor formally transcribed. MD Anderson team members took notes during the interviews. Following each semi-structured interview, the MD Anderson team reviewed the discussion which allowed the highlights of the call to be identified and agreed upon by the team.
Data Analysis
Following the semi-structured interviews, an MD Anderson team member compiled the data collection form responses with the semi-structured interview findings for each site into affinity diagrams. Affinity diagrams are a flexible and creative way to generate, organize, and understand a complex collection of data (Langley et al. 2009; PQ Systems n.d.; Tague 2004) . Using affinity diagram methods, data from each site were reviewed and divided by environmental level. Focus was placed on the oncology clinic and genetic counseling clinic level data, recurring topics were identified, and the specific data relevant to each of these topics were arranged categorically.
Affinity diagram processes allowed for clinic and process barriers to be identified. Ishikawa diagrams, also called fishbone diagrams, are a visual method to categorize and map barriers in a process that reduce the effectiveness of the process or impact the desired outcome, as seen in Fig. 2 (Tague 2005) . Potential barriers to the use of genetics services, or to the success of the QI project, were defined as anything that may impede patient access to genetics services or introduce variability into a process or system that would cause decreased accessibility of, efficiency of, timeliness of, or equitable access to genetics services. Potential facilitators of the use of genetics services, or to the success of the QI project, were also identified and were defined as anything that may improve the accessibility of, efficiency of, timeliness of, or equitable access to genetics services; decrease variability in clinical processes or systems that may interfere in the patient's receipt of genetics services; or removal of a barrier to genetics services.
A summary process flow diagram was created to visualize the process by which a patient of interest for the purpose of the QI project (diagnosed with breast or ovarian cancer) may interact with genetic counseling and genetic testing services during the course of their cancer diagnosis and treatment (Fig. 3) . Data to create the process flow diagram was obtained by combining findings from the internal and external assessments, highlighting the consistent steps and decision points across locations and oncology care settings.
Following the creation of the ES summary documents (affinity diagrams, Ishikawa diagrams, and the process flow diagram), these items were shared with the MD Anderson team internally as well as with each site team to identify discrepancies, errors, or accidental misrepresentation of the content. Summary documents were shared with each site 1 to 2 weeks following the completion of their interview with the MD Anderson team. All proposed edits or changes were made to the summary documents after feedback was received. There were no major disagreements or discrepancies identified upon review of documents. If this had occurred, the MD Anderson team would have deferred to the expertise of the individuals on each site team, and made adjustments as requested by the site. Descriptive statistics were used to summarize the data obtained during the ES process. 
Results
All steps of the ES process were completed within 6 months, and sufficient information was collected to compare the characteristics of each collaborating site and to create summary documents to guide QI project planning.
Internal Assessment Findings
The internal assessment component of the environmental scan included a review of MD Anderson's clinical cancer genetics services, internal processes, work flows, system barriers and facilitators, genetic counselor experiences in non-MD Anderson clinical environments, and lessons learned from the universal genetic testing initiative. There were several findings from the internal assessment that shaped the QI project dissemination planning process. First, MD Anderson's oncology and clinical cancer genetics services are unique in that patients are seen in cancer-specific clinics (e.g., breast cancer clinic, gynecologic oncology clinic, gastrointestinal cancer clinic). MD Anderson clinical cancer genetics services often require the involvement of a physician during the genetic counseling session. Additionally, genetic counselors in Texas do not have the opportunity to become licensed, and at MD Anderson, are not the ordering provider for genetic testing, nor do they have a role in billing for the sessions. Genetic counselor experiences in non-MD Anderson clinical environments helped the MD Anderson team to identify that these internal assessment findings may be unique and would likely be different in a community, non-academic hospital setting (e.g., cancer clinic structures, billing practices, experience working with data collection and analysis). Lessons learned from the universal genetic testing initiative at MD Anderson highlighted major challenges with data collection and management in terms of time and effort required, need for standardized data elements, data sources, and data collection processes; risks regarding identification of appropriate denominators; and challenges to measuring intervention impact when multiple activities were occurring simultaneously. Since the universal genetic testing initiative included various QI interventions in order to demonstrate a successful result, we acknowledged that it is unlikely for one clinical QI intervention to significantly impact an entire patient population and that several coordinated, small, and measureable interventions may need to occur before improvement can be seen. The internal assessment had a direct impact on the initial engagement strategy to include genetic counselors and clinical staff as early in the process as possible when discussing the idea for the QI project and when obtaining buy-in to proceed. The challenges surrounding data collection identified during the internal assessment shaped the MD Anderson team's approach to not require patient-level data or metrics to be reported in the data collection form or semi-structured interviews, and prompted the inclusion of questions in the data collection form about current data collection processes, tools, and capabilities. The internal assessment provided the MD Anderson team with topics, themes, and processes to anticipate and identify when conducting the semi-structured interviews and when analyzing the ES data.
External Assessment Findings
The data collection form questions were completed by the site teams in an average of 25 days. After compiling the results of were accurate at the completion of each ES. Abbreviations: GC: genetic counseling, EMR: electronic medical record, GT: genetic testing, FTE: full-time equivalent, Gyn. Onc.: Gynecologic Oncologist, hx: history three completed forms, including additional external data collection performed by the MD Anderson team, we found that 12 of the questions (9.2%) were unanswerable by all three site teams and that an additional 9 questions (6.9%) were unanswerable by two of the three site teams. The majority of these unanswerable questions pertained to the hospitalenvironmental level and oncology clinic-environmental level, representing specific areas for future data collection form refinement. The primary reason that questions were unanswerable by the site teams was due to absent or inaccessible information. For example, several regional-level data points were either not included or reported consistently across the sites' hospital Community Needs Assessment reports and therefore were left unanswered on the data collection form. Unanswerable hospital-level questions were also due to lack of data or limited access to hospital-level reports. For example, a data collection form question about the types of health insurance used by patients visiting the hospital or healthcare system was unknown by all three sites. This information either has never been collected by the hospital, has been collected but may not be publically available, or the site teams may be unaware of where or how to access their health system's report of such information. There were fewer oncology clinic-level questions that were consistently unanswerable by the three sites. Most unanswerable oncology clinic-level questions were due to lack of information regarding the practices of non-genetics health care providers in the clinic (e.g., research studies in the oncology clinic or how long it takes a patient newly diagnosed with cancer to schedule an appointment with an oncology provider). Answers to these type of questions may have been informative to assessing the broader hospital or oncology environment, but these unanswerable questions did not significantly limit or restrict the ability of the ES to assess each site for the purpose of QI project dissemination. The 130 questions in the data collection form were not comprehensive, as the semi-structured interviews included discussions of several additional topics that were important to understanding each site's unique processes and environment.
Further testing and refinement of the data collection form are required before it can be efficiently used beyond our ES process or generalized to other settings.
The site teams completed semi-structured interviews within 90 min. Topics discussed in all of the interviews can be divided by the same environmental levels used by the data collection form. In the regional-level, discussions about the availability of cancer genetic counseling services in the same geographic region or city as the collaborating site occurred in all three interviews. At the hospital-level, all interviews included discussions of the site's oncology and genetic counseling clinic locations. At the oncology clinic and genetic counseling clinic levels, all sites discussed the interactions between oncology and genetics clinics, identification of physicians who support genetic counselors and promote the services that they provide, observed patterns of oncology physician practices (clinical documentation, referral, and genetic testing), genetic counseling clinic structures and processes, and relevant peripheral projects (e.g., mammography screening projects, universal tumor screening for Lynch syndrome).
Following compilation of data collection form responses and semi-structured interview notes, the affinity diagrams for each site were created. Categories of data in the affinity diagrams included referrals and scheduling, physician practices, staffing and personnel, technology, genetic counseling practices and processes, and upcoming or anticipated changes. For example, one site had a data point in the referrals and scheduling category that stated, BReferrals for genetic counseling can be received by fax, email, phone, or the electronic medical system.^Affinity diagrams efficiently categorized relevant data from the ES, identified data to describe the setting, size, and characteristics of each site as shown in Table  2 , and identified barriers within these categories which were included in the Ishikawa diagram (Fig. 2) .
The ES identified potential barriers to patients receiving genetics services at each site, which were categorized using Ishikawa diagrams. All three Ishikawa diagrams were compiled to create Fig. 2 . The most commonly reported barriers were inconsistency and variability in physician referral to genetic counseling and coordination of genetic testing, and inefficient electronic medical record processes in tracking genetic counseling referrals and locating genetic testing results. Several of these barriers, such as variability and inconsistency, represent expected levels of variation that occur within any system in part due to human errors. Other barriers shown in Fig. 2 , such as requiring completion of paperwork and family history prior to scheduling for genetic counseling, or noting that 30-40% of patients seen for cancer genetic counseling have no personal history of cancer, represent clinic processes that were intentionally implemented for a specific purpose: reducing no-show rates, and accommodating requests for genetic counseling for any referred patient, respectively. These processes, however, have unintended consequences, such as becoming a barrier to patients whose diagnosis alone is sufficient to warrant genetic counseling and testing, or decreasing the availability of genetic counseling services for individuals undergoing diagnosis and treatment for cancers, whereby genetic testing results could impact treatment decisions. The ES also identified potential facilitators of patient receipt of cancer genetics services at each site, such as genetic counselors providing dedicated cancer genetic counseling services (rather than covering multiple genetic counseling specialties), and genetic counselors are hired directly by the hospital (Table 3) .
The ES process identified opportunities to enhance cancer genetics services using QI methods. For example, the commonly reported barrier of variability in physician referral to genetic counseling could be reduced or eliminated using QI interventions to create consistent or standardized processes for oncology clinics, provide physician education and tools to promote appropriate referrals, or share referral rates of each physician as a Breport card^to acknowledge their efforts and encourage improvement. The ES also identified areas for improvement which would increase genetic counseling clinic efficiency. For example, clinics where genetic counselors package their own genetic test kits could increase their efficiency by utilizing shared clinic or departmental resources to complete this task, and QI methods could be used to measure changes in efficiency and the unintended consequences of trying a new process. The QI pilot project may enhance cancer genetics services at each site by standardizing processes and encouraging collaboration across clinics in a way that positions the genetic counselors as team members in patients' oncology care, and as resources to support best practices, rather than risk being perceived as barriers to patient's receipt of recommended genetic testing. The ES identified specific clinic locations within each site's health care system that were requesting new or expanded availability of genetics services, or were developing telemedicine services to increase reach of oncology care. These opportunities could be leveraged to increase access to clinical cancer genetics services, and incorporating QI approaches to these new clinics could ensure that services are provided in an efficient, standardized manner, or by setting parameters around these new clinical services to ensure best use of genetic counselor time and promote genetic counselors working at the top of their license or scope of practice. Also, the ES identified threats to the success of the QI project, which included limited time for genetic counselors to invest in non-patient care activities, risk of miscommunication or misperception of the QI project's purpose among physicians and hospital stakeholders, and lack of existing methods for collecting and analyzing QI data.
The MD Anderson team used ES data to create the process flow diagram in Fig. 3 , which shows the typical steps a patient takes when accessing and using cancer genetics services at any of the three collaborating sites. The process flow diagrams were used to plot where site-specific barriers to and facilitators of cancer genetics services occurred, where interventions could be added to address barriers and identified areas for improvement, and identified the points in the process at which QI metric collection (specific data points) should occur in order to assess and interpret the impact of QI interventions on the rates of guideline adherence and patient receipt of genetics services.
Discussion
The MD Anderson team created an ES specific to cancer genetics services and efficiently used it to collect information needed to plan the dissemination of a cancer genetics QI project to three unique oncology care settings. Each component of the ES played an important role in understanding the environment and identifying opportunities for improvement at the collaborating sites. The internal assessment components informed the design of dissemination processes and development of the external assessment components, and the external assessment components provided data to guide QI project planning. No single component of the ES alone would have been sufficient for collecting the information needed to plan, tailor, and support QI project dissemination and implementation at each site. Using the ES as a process of information gathering, as shown in Fig. 1 , rather than as a discrete tool, allowed for flexibility and tailored data collection and promoted communication and team building within and among the sites.
The ES identified barriers to, and facilitators of patient's access to and receipt of cancer genetics services, as well as opportunities and threats to QI project implementation at each collaborating site. Clinical QI interventions will be developed that will leverage the information gathered by the ES to target identified barriers to, or inefficiencies in cancer genetics services. The ES data will also guide the integration of the QI project into a site's environment and will use the identified facilitators and opportunities to promote the future success of the QI project, and to guide sustainable and acceptable changes and improvements. The ES provided an assessment of the ability of each collaborating site to undertake the QI project and identified potential threats to the project's success. For example, in anticipation of having limited resources for data abstraction, metric reporting, and information technology support at each site, the MD Anderson team created a centralized, secure REDCap database with discrete fields to increase the accuracy and consistency of data collection (Harris et al. 2009 ). To streamline QI metric calculation and reporting, the MD Anderson team applied a code to the REDCap database that will create automated e-mail reports of each site's monthly QI metrics. The ES included a systems-level perspective, which helped identify potential barriers to, and inefficiencies in patient access and receipt of cancer genetics services not previously reported in the literature. Previously unreported barriers included the inability to track incoming referrals to genetic counseling, inability to measure the outcomes of genetic counseling referrals, inefficiencies in genetic counseling appointment scheduling processes, difficulties in obtaining patients' genetic information (prior genetic counseling appointment notes and genetic test results) from electronic medical records, and use of a substantial proportion of genetic counseling appointments to meet with individuals without a personal history of cancer nor a known familial mutation. This final finding represents a patient population with a lower likelihood of having a hereditary predisposition to cancer that may indicate inefficient use of genetic counseling or clinical resources and may be an opportunity to use different service delivery models.
Many of the barriers to guideline adherence and patient receipt of genetic counseling that were found during the ES were previously reported in the literature and support the existence and prevalence of these barriers in clinical cancer genetics settings. These barriers included inconsistent or lack of referral for genetics services from a medical provider or physician, lack of knowledge dissemination to medical providers or physicians regarding guidelines for genetics referral or testing, and perceived or real lack of genetic counseling appointment availability (Brown et al. 2005; Burgess et al. 2016; Calzone et al. 2005; Chun et al. 2016; Cragun et al. 2015; Delikurt et al. 2015; Demsky et al. 2013; Douma et al. 2016; Eichmeyer et al. 2014; Elnahal et al. 2017; Hamilton et al. 2016; Kinney et al. 2014; Macdonald et al. 2012; McCarthy et al. 2016; Nair et al. 2017; Ridge et al. 2009; Schwartz et al. 2014; Sperber et al. 2016; Stuckey et al. 2014; Sussner et al. 2011; Vadaparampil et al. 2015; Willis et al. 2016) .
Since MD Anderson Cancer Center is a large, tertiary care center focusing specifically on cancer diagnosis, treatment, and research, the MD Anderson team expected the sites who are members of the MD Anderson Cancer Network® to have unique differences in their health care environments as compared to MD Anderson. Differences were noted when comparing the internal assessment findings with those of the individual sites (such as genetic counselor state licensure availability, cancer-specific genetics clinics versus general cancer genetics clinics, and the MD Anderson team's prior experience with QI methods). More importantly, similarities were identified in clinical referral, genetic counseling, and genetic testing processes; the steps a patient would encounter as demonstrated in the process flow diagram in Fig. 3 ; risks to implementing a QI project such as data collection burdens and staffing challenges; and a desire to ensure that all eligible patients receive high quality, guideline-based genetics services as noted as a facilitator in Table 3 . The similarities between cancer genetics processes, potential risks and challenges, and patient-centered goals of MD Anderson and the three sites' teams are significant strengths that may improve the likelihood of the QI pilot project's success.
Limitations
We acknowledge several limitations of our ES process and findings. First, the foundation for disseminating our QI project is the assumption that the rates of guideline-based cancer genetics service use by patients with ovarian cancer or TNBC are lower than 80%, as this would be consistent with the current rates reported in the literature. If upon collection of baseline and prospective clinical data, we observe high rates of guideline adherence and patient receipt of genetics services, we plan to expand our patient population to include patients with other cancer types, as opportunities for project expansion were identified during the ES. Second, the barriers to, and facilitators of patient receipt of genetics services identified and reported herein, are based on the observations, perceptions, and experiences of the teams at the three sites. At this time, we do not have data to verify or quantify the presence or magnitude of the reported barriers or the actual impact of these barriers on patient access to or use of genetics services. We hope to better quantify the presence, absence, impact, and interaction of ES identified barriers and facilitators via continuous QI-driven PDSA-cycles and QI metric collection. Third, we created and implemented the ES using QI-based, nonsystematic methodologies, which may have affected the validity of our ES process. However, an ES is intended to be a rapid, cost-effective, mixed-methods, first step in planning strategies or projects, and is not intended for obtaining or producing generalizable information.
Practice Implications
The ES process described herein may be adapted for use by other clinical genetic counseling specialties seeking to expand access to their best practices, prepare for QI dissemination, or develop other clinical genetics programs or initiatives. Genetic counselor-led teams completed the ES by working together with team members to collect and discuss data, which encourages collaboration within a hospital site or health care system. Semi-structured interviews occurred between genetic counselors at each site and within the MD Anderson team, which allowed for a high-level, detailed discussion of clinic processes. Collaboration among peers to perform such clinic assessments may allow for the incorporation of outside perspectives to identify otherwise unnoticed barriers to, and facilitators of guideline adherence or clinic processes, and may promote sharing of creative opportunities, methods, or tools for QI initiatives. To disseminate our QI project, the MD Anderson team used an existing network of health systems, which may serve as a pathway for other health care networks or genetics specialties to perform peer-to-peer ES and genetics service evaluations. Our efforts represent a cancer genetics-specific application of the processes recommended for Learning Health Systems, which seek to translate and leverage research and scientific knowledge to continually improve clinical care (Greene et al. 2012; Grumbach et al. 2014) .
For individual genetics clinics seeking to perform their own QI projects, there are various QI methods available such as Six Sigma, The Model for Improvement, and Lean. Each of these QI methods have benefits and limitations, and should be assessed in terms of their relevance to the intended aims or goals of a QI project. There is also a growing body of literature to describe single-institution or single-clinic QI efforts, including projects specific to cancer genetics, which may help those seeking to initiate a project at their location or clinic.
Research Recommendations
In future efforts to design or plan health care QI initiatives and project dissemination, investigators should seek to evaluate the usefulness, acceptability, feasibility, and validity of the ES in project and program planning. We will continue to evaluate and refine the ES process described herein so that it can be used to assess cancer genetics services efficiently in other clinics, institutions, or genetics specialties for the purpose of QI project design and planning. The ES process described here was limited to a small number of sites and required the presence of cancer genetic counselors in order to evaluate the dissemination process as a pilot project. The MD Anderson team plans to perform the ES process to assess additional sites for further QI dissemination. Sites without genetic counselors may be included in future uses of the ES, which will be an opportunity for the ES to capture similarities and differences in practices and processes, as compared to the sites described here. A benefit of the ES process is its flexibility, and future efforts will continue to refine and adapt the ES process in order to effectively collect information about cancer genetics services in other, unique oncology care settings.
Future research in this area should aim to better understand the role of the health care system and its potential to influence clinical processes, barriers to, and facilitators of patient access and use of cancer genetic counseling. Improved identification and understanding of clinical systems and processes will help to support broader efforts to increase guideline adherence, and may increase the efficiency of existing cancer genetic counseling services in a time when the demand for these services often exceeds the supply of trained genetic counselors and genetics professionals.
Conclusion
An ES was created and used to assess cancer genetics services in three unique oncology care settings. ES findings contributed to the existing knowledge of barriers to patient receipt of genetics services and identified several barriers not previously reported in the literature. An ES may be an efficient way to evaluate cancer genetics services in other health systems and may be applied to other clinical genetics specialties seeking to design or implement QI initiatives.
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